Cargando…

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

OBJECTIVE: To assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout. METHODS: In this international, 6-month, open-label trial,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schiff, M, Pritchard, C, Huffstutter, J E, Rodriguez-Valverde, V, Durez, P, Zhou, X, Li, T, Bahrt, K, Kelly, S, Le Bars, M, Genovese, M C
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2009
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756956/ https://www.ncbi.nlm.nih.gov/pubmed/19074911 http://dx.doi.org/10.1136/ard.2008.099218

Ejemplares similares

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data
por: Dougados, M, et al.
Publicado: (2008)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study
por: D'Agostino, Maria-Antonietta, et al.
Publicado: (2016)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells, Alvin F, et al.
Publicado: (2014)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
por: Schiff, Michael, et al.
Publicado: (2016)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Abatacept as a Therapeutic Option for Rheumatoid Vasculitis
por: Al Attar, Layth, et al.
Publicado: (2018)

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives
por: Noisette, Ashley, et al.
Publicado: (2018)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

Abatacept in psoriatic arthritis: Case report and short review
por: Ursini, Francesco, et al.
Publicado: (2013)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

Current treatment options for psoriatic arthritis: spotlight on abatacept
por: Ursini, Francesco, et al.
Publicado: (2018)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
por: Sokolove, Jeremy, et al.
Publicado: (2016)

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
por: Degboé, Yannick, et al.
Publicado: (2020)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Lundquist, Lisa M, et al.
Publicado: (2012)

SNP algorithms for prediction of efficacy and adverse events of abatacept (ABT)
por: Middleton, James E, et al.
Publicado: (2012)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_moljpma3k0915k9jj69tf4lu3i